ArticleBiological trace element research2026
Cd-IMAC-MS Enables Exploratory Profiling of Cadmium-Associated Proteins in Rat Brain after Cadmium Exposure.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cadmium (Cd²⁺) is a persistent neurotoxic metal, but the brain proteins recoverable by cadmium-affinity enrichment after exposure remain incompletely defined. We developed cadmium-immobilized metal affinity chromatography coupled with mass spectrometry (Cd-IMAC-MS), which combines non-denaturing Cd²⁺-charged nitrilotriacetic acid (Cd-NTA) affinity recovery, blank-NTA controls, and data-independent acquisition (DIA) proteomics. The discovery experiment comprised 12 independent animals in a balanced 2 × 2 exposure-by-affinity-matrix design (n = 3 per cell). For 2,119 proteins quantified across all four cells, an ordinary least-squares interaction screen identified 26 nominal candidates (10 positive and 16 negative interaction effects); none met Benjamini-Hochberg-adjusted q < 0.05. A separate Cd-NTA-only CH - CL branch identified 23 nominal candidates (six positive and 17 negative effects), yielding a 49-protein exploratory union; no protein met q < 0.05 after pooled adjustment across 2,988 discovery tests. In a lower-dose prefrontal-cortex cohort, 775 of 8,209 proteins met nominal P < 0.05 and none met q < 0.05. Six symbols overlapped the discovery set, and CTBP1 and PDHA1 also occurred in the Comparative Toxicogenomics Database list. Because no standalone sample-ID-to-treatment key was available, the reported meanCon-meanCase signs were not assigned an exposure direction. The functional-context analysis, protein-association network, database annotations, and residue-level predictions are interpreted as secondary, hypothesis-generating evidence. Cd-IMAC-MS therefore prioritizes candidates for orthogonal binding and functional validation rather than establishing direct in vivo Cd²⁺ binding.
Indexed as
Identifiers
42742917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.